Traded Oct 2 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Planned for Oct 2, 2026 · Notice filed Oct 2, 2026
A Nurix Therapeutics officer told the SEC about a plan to sell $135K of Nurix Therapeutics shares around Oct 2, 2026. The filing says the shares were acquired as compensation.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded Oct 2 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Christine Ring (Chief Legal Officer) sold ~$134K of Nurix Therapeutics
Planned saleTraded Oct 2 · filed the same day
Derivative exercise or conversion — not an open-market buy.